Nkcfo LLC Makes New Investment in Alpha Teknova, Inc. (NASDAQ:TKNO)

Nkcfo LLC purchased a new stake in Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 60,000 shares of the company's stock, valued at approximately $501,000. Nkcfo LLC owned 0.11% of Alpha Teknova at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Alpha Teknova in the 4th quarter valued at $94,000. Whalen Wealth Management Inc. purchased a new position in Alpha Teknova during the 4th quarter worth $240,000. State Street Corp grew its stake in Alpha Teknova by 249.3% during the 3rd quarter. State Street Corp now owns 76,645 shares of the company's stock worth $371,000 after buying an additional 54,700 shares during the last quarter. Geode Capital Management LLC grew its stake in Alpha Teknova by 24.4% during the 3rd quarter. Geode Capital Management LLC now owns 188,173 shares of the company's stock worth $911,000 after buying an additional 36,914 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Alpha Teknova during the 3rd quarter worth $1,483,000. 13.81% of the stock is currently owned by hedge funds and other institutional investors.

Alpha Teknova Stock Down 3.0 %

TKNO stock traded down $0.24 on Wednesday, hitting $7.88. 458,951 shares of the company's stock were exchanged, compared to its average volume of 232,389. Alpha Teknova, Inc. has a 12-month low of $1.15 and a 12-month high of $10.37. The firm has a 50 day moving average price of $8.49 and a two-hundred day moving average price of $6.69. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.94 and a current ratio of 4.73. The stock has a market cap of $420.08 million, a P/E ratio of -10.65 and a beta of 0.34.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on Alpha Teknova in a research note on Monday, February 10th. They set a "buy" rating and a $12.00 target price on the stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.